[Use of mitomycin C (MMC) for dacryocystorhinostomy interventions].
Mitomycin C (MMC) has been described as having a positive effect in different types of dacryocystorhinostomy (DCR) surgery such as external DCR, endonasal and transcanalicular DCR. MMC, an antineoplastic antibiotic, acts as an alkylating agent by inhibiting DNA, RNA and protein synthesis. Topical use of MMC can modulate the scarring process, which is useful in glaucoma surgery and pterygium excision. In DCR, MMC is also useful because it reduces the scarring process and thus prevents the occlusion of the osteotomy site related to the fibroblast activity. An increase in the success rate for long-term results has been observed by different authors, resulting from a larger osteotomy size as well as a decrease in the density and cellularity of the mucosa. No complications have been seen with topical use of MMC.
Service d'Ophtalmologie, CHU Dupuytren, 87042 Limoges, France. jp-adenis@wanadoo.fr
J-P
JP
Adenis
U
U
Sommer
P-Y
PY
Robert
D002921:Cicatrix / Q000209:etiology / Q000517:prevention & control*; D003608:Dacryocystorhinostomy / Q000009:adverse effects*; D006801:Humans; D007766:Lacrimal Apparatus Diseases / Q000209:etiology / Q000517:prevention & control*; D016685:Mitomycin / Q000627:therapeutic use*; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use*
D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin